Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Brii Biosciences Limited ( (HK:2137) ) has provided an update.
Brii Biosciences Limited has announced its classification as a Passive Foreign Investment Company (PFIC) for the taxable year ending December 31, 2024. This status affects U.S. shareholders, who may elect to treat the company as a Qualified Electing Fund (QEF) by filing Form 8621 with their federal income tax returns. The announcement provides necessary information for shareholders to make this election, which requires them to include their share of the company’s ordinary earnings and net capital gains in their income. The company advises shareholders to consult tax advisors regarding the implications of this PFIC status.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biopharmaceutical company incorporated in the Cayman Islands, primarily focused on developing therapies for infectious diseases. The company operates in collaboration with its subsidiary, TSB Pharmaceutical Co. Limited, and is listed on the Hong Kong Stock Exchange under the stock code 2137.
YTD Price Performance: 156.67%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €233M
Learn more about 2137 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue